Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or to sound), have a reduced ability to function, or require bed rest. Despite its high prevalence and impairment, migraine is often not recognized or effectively treated.
Interventions of interest:
- Erenumab (Amgen/Novartis)
- Fremanezumab (Teva)
- Galcanezumab (Eli Lilly)
Below you will find the final documents from the assessment review process: